Leerink Partners Raises IDXX Price Target to $600, Maintains 'Outperform' Rating

Leerink Partners analyst Daniel Clark raises IDEXX Laboratories' (IDXX) price target to $600 from $580, a 3.45% increase, while reaffirming his "Outperform" rating. The average analyst target price is $531.30, with a high estimate of $625.00 and a low estimate of $389.92, indicating a potential 2.43% upside. GuruFocus estimates a one-year GF Value of $571.11, suggesting a 10.1% upside from the current price.

Leerink Partners analyst Daniel Clark has raised the price target for IDEXX Laboratories (IDXX) to $600 from $580, representing a 3.45% increase. The analyst maintains an "Outperform" rating on the stock. This adjustment comes after thorough channel checks and insights from a semiannual survey conducted with veterinarians, reflecting continued confidence in IDEXX's strategic positioning and growth prospects [1].

The updated price target of $600 aligns with the average one-year target price of $531.30, as forecasted by 13 analysts. The high estimate of $625.00 and the low estimate of $389.92 suggest a potential upside of 2.43% from the current price of $518.71 [2].

GuruFocus estimates a one-year GF Value of $571.11 for IDEXX Laboratories, suggesting a 10.1% upside from the current price of $518.71. This estimate is based on historical multiples, past business growth, and future performance estimates [2].

IDEXX Laboratories reported a 5% organic revenue growth in Q1 2025, driven by strong performance in CAG Diagnostics and veterinary software. The company also achieved a 9% expansion in its premium instrument install base and reported a 10% organic growth in IDEXX VetLab consumable revenues. However, the company faced challenges such as a 2.6% decline in US clinical visits and a 13% decline in CAG premium instrument placements compared to high prior year levels [2].

IDEXX Laboratories continues to position itself strongly in the veterinary healthcare sector, with a healthy balance sheet and a positive outlook for 2025. The company's 2025 revenue guidance is $4,095 million to $4,210 million, with a 6% to 9% organic growth outlook, and the EPS guidance is $11.93 to $12.43 per share, with an 8% to 12% comparable EPS growth [2].

References:
[1] https://www.gurufocus.com/news/2985882/idxx-analyst-leerink-partners-raises-price-target-to-600-idxx-stock-news
[2] https://www.gurufocus.com/news/2983331/idexx-laboratories-idxx-sees-raised-price-target-from-leerink-analyst-idxx-stock-news